A buyout soon ... would be a stretch in my opinion after seeing the video again.
On the video, Rob Hutchinson says : "if you look at the top 50 Pharmas there probably isn't one that wouldn't have an interest ... we would look to license TRANSCEND Vector off to multiple, multiple biotech or biopharmaceutical companies."
He later mentions "hitting it out of the ballpark (and that) the next 6 to 9 months is going to be very much proving...starting to see therapeutic compounds go from pre-clinical to clinical trials ... and with a partner...and that's going to be a really exciting time".
Looks to me that with 50 majors as potential clients, why would he even conemplate a buyout? Also, the possibility exists that licenses even for one compound could be granted to different companies for different global regions. The potential is absolutely mind boggling!
The "6 to 9 months" part is intriguing as the plan plays out. Also, who is the 'partner' he refers to?
Imagine what kind of buyout price would be needed too compete with the potential! Who could or even would make that kind of an offer at this early stage? It just doesn't make any sense to take anything under at least $25...and even that could be far too cheap.